The Swiss dermatology giant announced Tuesday it has agreed to purchase the medical-grade skincare brand from Blackstone Tactical Opportunities and the Obagi family. Executives confirmed the $1.5 billion deal will allow Galderma to vertically integrate the lucrative process of making consumers feel deeply unsettled about their own faces.
Galderma executives told analysts the acquisition provides a crucial foothold in the high-margin preventative terror sector. By absorbing ZO Skin Health’s pipeline of aggressive chemical exfoliants and proprietary retinols, the company aims to right-size the self-esteem of a wealthy, aging demographic that currently possesses too much disposable income and an insufficient amount of epidermal shame.
For Blackstone, the sale represents a highly successful exit from the human face market. The private equity behemoth first took a stake in the Obagi family's enterprise to extract maximum shareholder value from microscopic wrinkles, a strategy that generated massive returns as the fund leveraged the natural degradation of collagen into a steady stream of quarterly dividends.
By bringing this brand in-house, we can finally control the entire supply chain of vanity, from the initial terrifying consultation in a dermatologist's chair to the mandatory $400 daily maintenance serum.
In an afternoon regulatory filing, the company noted that the premium valuation was easily justified by the target's loyal customer base, whose faces are now structurally dependent on the continued financial solvency of a Swiss pharmaceutical conglomerate.